TickerFacts.

Compare

Arcus Biosciences, Inc. vs Akebia Therapeutics, Inc. vs Arvinas, Inc. vs Puma Biotechnology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearArcus Biosciences, Inc.
RCUS		Akebia Therapeutics, Inc.
AKBA		Arvinas, Inc.
ARVN		Puma Biotechnology, Inc.
PBYI
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$247.00M$236.20M$262.60M$228.37M
Revenue growth (YoY)-4.3%+47.5%-0.3%-0.9%
Gross marginn/a83.3% (computed)n/a74.5% (computed)
Operating margin-156.3%9.9%-45.1%16.3%
Net margin-142.9%-2.3%-30.8%13.6%
Net income-$353.00M-$5.34M-$80.80M$31.11M
EPS (Diluted)-$3.29-$0.02-$1.14$0.61
Operating cash flow-$482.00M$67.99M-$273.80M$41.80M
Free cash flow-$484.00M$67.70M-$275.70M$41.73M
Cash & equivalents$222.00M$184.84M$142.90M$29.64M
Total assets$1.14B$376.56M$717.90M$216.30M
Total liabilitiesn/a$343.95M$284.00M$85.96M
Shareholders' equity$631.00M$32.61M$433.90M$130.34M
Return on year-end equity-55.9%-16.4%-18.6%23.9%
Shares outstanding125.30M265.42M63.50M50.41M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearArcus Biosciences, Inc.Akebia Therapeutics, Inc.Arvinas, Inc.Puma Biotechnology, Inc.
Latest$247.00M
Ended 2025-12-31		$236.20M
Ended 2025-12-31		$262.60M
Ended 2025-12-31		$228.37M
Ended 2025-12-31
1 year earlier$258.00M
Ended 2024-12-31		$160.18M
Ended 2024-12-31		$263.40M
Ended 2024-12-31		$230.47M
Ended 2024-12-31
2 years earlier$117.00M
Ended 2023-12-31		$194.62M
Ended 2023-12-31		$78.50M
Ended 2023-12-31		$235.64M
Ended 2023-12-31
3 years earlier$112.00M
Ended 2022-12-31		$292.48M
Ended 2022-12-31		$131.40M
Ended 2022-12-31		$228.03M
Ended 2022-12-31
4 years earlier$383.00M
Ended 2021-12-31		$211.65M
Ended 2021-12-31		$53.60M
Ended 2021-12-31		$253.16M
Ended 2021-12-31